Effentora

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

fentanil

Available from:

Teva B.V.

ATC code:

N02AB03

INN (International Name):

fentanyl

Therapeutic group:

Analgetiki

Therapeutic area:

Pain; Cancer

Therapeutic indications:

Zdravilo Effentora je indicirano za zdravljenje prebijajoče bolečine (BTP) pri odraslih z rakom, ki že prejemajo vzdrževalno opioidno terapijo za kronično bolečino pri raku. BTP je prehodno akutne bolečine, ki se pojavi na ozadju, ki se sicer pod nadzorom vztrajno bolečina. Bolniki, ki prejemajo preživnino opioidne terapije so tisti, ki so pri čemer se vsaj 60 mg oralno morfin dnevno, vsaj 25 micrograms od transdermalni fentanil na uro, vsaj 30 mg oxycodone dnevno, vsaj 8 mg oralno hydromorphone dnevno ali equianalgesic odmerek drugo opioidov za teden dni ali več.

Product summary:

Revision: 28

Authorization status:

Pooblaščeni

Authorization date:

2008-04-04

Patient Information leaflet

                                30
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v originalni ovojnini za zagotovitev zaščite pred vlago.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
TEVA B.V. Swensweg 5 2031 GA Haarlem Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET
EU/1/08/441/001
EU/1/08/441/002
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Effentora 100
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC:
SN:
NN:
31
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT S 4 TABLETAMI
1.
IME ZDRAVILA
Effentora 100 mikrogramov bukalne tablete
fentanil
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
TEVA B.V.
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
1. Odtrgajte
2. Prepognite
3. Odluščite
32
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Effentora 200 mikrogramov bukalne tablete
fentanil
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena bukalna tableta vsebuje 200 mikrogramov fentanila (v obliki
citrata).
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje natrij. Za več informacij glejte navodilo za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
4 bukalne tablete
28 bukalnih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
oralna uporaba
Vstavite v ustno votlino. Tablete ne sesajte, ne žvečite in ne
pogoltnite cele. Pred uporabo preberite
priloženo navodilo!
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
ZDRAVILO SHRANJUJTE NEDOSEGLJIVO OTROKOM!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
ZDRAVILO SMEJO UPORABLJATI SAMO BOLNIKI, KI ŽE PREJEMAJO VZDRŽEVALNO
OPIOIDNO ZDRAVLJENJE ZA
KRONIČNO BOLEČINO PRI RAKU.
Preberite priloženo navodilo za uporabo, ki vsebuje pomembna
opozorila
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Effentora 100 mikrogramov bukalne tablete
Effentora 200 mikrogramov bukalne tablete
Effentora 400 mikrogramov bukalne tablete
Effentora 600 mikrogramov bukalne tablete
Effentora 800 mikrogramov bukalne tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Effentora 100 mikrogramov bukalne tablete
Ena bukalna tableta vsebuje 100 mikrogramov fentanila (v obliki
citrata).
Pomožna snov z znanim učinkom: Ena tableta vsebuje 10 mg natrija.
Effentora 200 mikrogramov bukalne tablete
Ena bukalna tableta vsebuje 200 mikrogramov fentanila (v obliki
citrata).
Pomožna snov z znanim učinkom: Ena tableta vsebuje 20 mg natrija.
Effentora 400 mikrogramov bukalne tablete
Ena bukalna tableta vsebuje 400 mikrogramov fentanila (v obliki
citrata).
Pomožna snov z znanim učinkom: Ena tableta vsebuje 20 mg natrija.
Effentora 600 mikrogramov bukalne tablete
Ena bukalna tableta vsebuje 600 mikrogramov fentanila v obliki
citrata).
Pomožna snov z znanim učinkom: Ena tableta vsebuje 20 mg natrija.
Effentora 800 mikrogramov bukalne tablete
Ena bukalna tableta vsebuje 800 mikrogramov fentanila (v obliki
citrata).
Pomožna snov z znanim učinkom: Ena tableta vsebuje 20 mg natrija.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
bukalna tableta
Effentora 100 mikrogramov bukalne tablete
Ploska, bela, okrogla prirezana tableta z oznako ‘C’ na eni strani
in na drugi strani ‘1’.
Effentora 200 mikrogramov bukalne tablete
Ploska, bela, okrogla prirezana tableta z oznako ‘C’ na eni strani
in na drugi strani ‘2’.
Effentora 400 mikrogramov bukalne tablete
Ploska, bela, okrogla prirezana tableta z oznako ‘C’ na eni strani
in na drugi strani ‘4’.
Effentora 600 mikrogramov bukalne tablete
Ploska, bela, okrogla prirezana tableta z oznako ‘C’ na eni strani
in na drugi strani ‘6’.
Effentora 800 mikrogramov bukalne tablete
Ploska, bela, okrogla prirezana tableta z oznako ‘C’ na eni strani
in na drugi strani ‘8’.
3
4.
KLINIČNI
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-04-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-04-2024
Public Assessment Report Public Assessment Report Bulgarian 14-04-2014
Patient Information leaflet Patient Information leaflet Spanish 04-04-2024
Public Assessment Report Public Assessment Report Spanish 14-04-2014
Patient Information leaflet Patient Information leaflet Czech 04-04-2024
Public Assessment Report Public Assessment Report Czech 14-04-2014
Patient Information leaflet Patient Information leaflet Danish 04-04-2024
Public Assessment Report Public Assessment Report Danish 14-04-2014
Patient Information leaflet Patient Information leaflet German 04-04-2024
Public Assessment Report Public Assessment Report German 14-04-2014
Patient Information leaflet Patient Information leaflet Estonian 04-04-2024
Public Assessment Report Public Assessment Report Estonian 14-04-2014
Patient Information leaflet Patient Information leaflet Greek 04-04-2024
Public Assessment Report Public Assessment Report Greek 14-04-2014
Patient Information leaflet Patient Information leaflet English 04-04-2024
Public Assessment Report Public Assessment Report English 14-04-2014
Patient Information leaflet Patient Information leaflet French 04-04-2024
Public Assessment Report Public Assessment Report French 14-04-2014
Patient Information leaflet Patient Information leaflet Italian 04-04-2024
Public Assessment Report Public Assessment Report Italian 14-04-2014
Patient Information leaflet Patient Information leaflet Latvian 04-04-2024
Public Assessment Report Public Assessment Report Latvian 14-04-2014
Patient Information leaflet Patient Information leaflet Lithuanian 04-04-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-04-2024
Public Assessment Report Public Assessment Report Lithuanian 14-04-2014
Patient Information leaflet Patient Information leaflet Hungarian 04-04-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 04-04-2024
Public Assessment Report Public Assessment Report Hungarian 14-04-2014
Patient Information leaflet Patient Information leaflet Maltese 04-04-2024
Public Assessment Report Public Assessment Report Maltese 14-04-2014
Patient Information leaflet Patient Information leaflet Dutch 04-04-2024
Public Assessment Report Public Assessment Report Dutch 14-04-2014
Patient Information leaflet Patient Information leaflet Polish 04-04-2024
Public Assessment Report Public Assessment Report Polish 14-04-2014
Patient Information leaflet Patient Information leaflet Portuguese 04-04-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 04-04-2024
Public Assessment Report Public Assessment Report Portuguese 14-04-2014
Patient Information leaflet Patient Information leaflet Romanian 04-04-2024
Public Assessment Report Public Assessment Report Romanian 14-04-2014
Patient Information leaflet Patient Information leaflet Slovak 04-04-2024
Public Assessment Report Public Assessment Report Slovak 14-04-2014
Patient Information leaflet Patient Information leaflet Finnish 04-04-2024
Public Assessment Report Public Assessment Report Finnish 14-04-2014
Patient Information leaflet Patient Information leaflet Swedish 04-04-2024
Public Assessment Report Public Assessment Report Swedish 14-04-2014
Patient Information leaflet Patient Information leaflet Norwegian 04-04-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 04-04-2024
Patient Information leaflet Patient Information leaflet Icelandic 04-04-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 04-04-2024
Patient Information leaflet Patient Information leaflet Croatian 04-04-2024
Public Assessment Report Public Assessment Report Croatian 14-04-2014

Search alerts related to this product

View documents history